MedicaidSeptember 21, 2023
Clinical Criteria updates - June 2023
On August 19, 2022, September 12, 2022, February 24, 2023, May 19, 2023, June 12, 2023, and July 11, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff.
Note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Document number | Clinical Criteria title | New or revised |
December 27, 2023 | *CC-0243 | Vyjuvek (beremagene geperpavec) | New |
December 27, 2023 | *CC-0242 | Epkinly (epcoritamab-bysp) | New |
December 27, 2023 | *CC-0241 | Elfabrio (pegunigalsidase alfa-iwxj) | New |
December 27, 2023 | CC-0228 | Leqembi (lecanemab) | Revised |
December 27, 2023 | *CC-0061 | Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications | Revised |
December 27, 2023 | *CC-0015 | Infertility and HCG Agents | Revised |
December 27, 2023 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised |
December 27, 2023 | CC-0151 | Yescarta (axicabtagene ciloleucel) | Revised |
December 27, 2023 | *CC-0177 | Zilretta (triamcinolone acetonide extended-release) | Revised |
December 27, 2023 | CC-0149 | Select Clotting Agents for Bleeding Disorders | Revised |
December 27, 2023 | CC-0032 | Botulinum Toxin | Revised |
December 27, 2023 | *CC-0002 | Colony Stimulating Factor Agents | Revised |
December 27, 2023 | *CC-0001 | Erythropoiesis Stimulating Agents | Revised |
December 27, 2023 | *CC-0174 | Kesimpta (ofatumumab) | Revised |
December 27, 2023 | *CC-0209 | Leqvio (inclisiran) | Revised |
December 27, 2023 | *CC-0011 | Ocrevus (ocrelizumab) | Revised |
CABC-CD-036878-23-CPN36110
PUBLICATIONS: October 2023 Provider Newsletter
To view this article online:
Visit https://providernews.anthem.com/california/articles/clinical-criteria-updates-june-2023-15616
Or scan this QR code with your phone